Vol. 8 (04) pp. 970-973 DOI: 10.21474/IJAR01/10866

STATINS IN THE PREVENTION OF DIABETIC MICROVASCULAR DISEASE - A STUDY IN 100 TYPE 2 DIABETIC PATIENTS IN RURAL POPULATION

, and
  • Department of General Medicine, Maharjahas Institute of Medical Sciences, Nellimarla 535217, South India.
5 Downloads 58 Views
Crossref

Download Full Paper (PDF)

Abstract

Study involving 100 patients of type 2 DM ? with microvascular complications (renal, retinal, neuronal, cardiovascular and Erectile Dysfunction) - benefits of statins.

Keywords

Article Analytics

References

  1. Zambon A et al. The role of finofibrate in clinical practice.? 2007;? Vol. 4 (suppl.3): 15-20
  2. Gupta A et al. Lipid lowering drug Atrovastatin as an adjunct in the management of diabetic macular edema.? Am J Opthal.? 2004 Apr; 137(4); 675-82.
  3. Chaturvedi N: The Epidemiology of Diabetis Mellitus:? An International Perspective.? International J of Epidemiology 2002;? 31:? 878.
  4. Leiter LA. The? prevention of diabetic microvascular complications :? Is there a role for lipid lowering ?? Diabetis Research and? Clinical Practice.? 2005;? ? 68 (Suppl.2):? S3-S14.
  5. Carmena R. Type 2 diabetis, dyslipidemia and vascular risk:? Rationale and evidence for correcting the lipid imbalance.? American Heart Journal.? 2005;? ? 150(5): 859 ? 870.
  6. Hoogwewrf BJ. Complications of Diabetis Mellitus.? Int J Diab Dev Ctries 2005;? 25: 63-9.
  7. Koh KK. Additional Beneficial Effects of Finofibrate Cobmined with Atorvastatin? in the Treatment of Combined? ? Journal of the American College of Cardiology.? 2005;? Vol.? 45 (10):? 1649-1653.

How to Cite This Article

B. Madhava Rao, Gowtham B. and Satyakumar K (2020); STATINS IN THE PREVENTION OF DIABETIC MICROVASCULAR DISEASE - A STUDY IN 100 TYPE 2 DIABETIC PATIENTS IN RURAL POPULATION, Int. J. of Adv. Res., 8 (04), 970-973, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/10866

Corresponding Author

B. Madhava Rao

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.